Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINOXIDIL EXTRA STRENGTH (FOR MEN) vs HYDRALAZINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.
Vasodilation of arterioles by direct relaxation of vascular smooth muscle, likely involving interference with calcium movement.
Treatment of androgenetic alopecia (male pattern baldness) in men,Off-label: female pattern hair loss, alopecia areata, chemotherapy-induced alopecia, beard enhancement
Hypertension,Heart failure (adjunctive therapy)
Topical: 1 m L of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 m L (100 mg).
Oral: Initiate with 10 mg 4 times daily for 2-4 days, then increase to 25 mg 4 times daily for the remainder of the week, then titrate to 50 mg 4 times daily. Maximum daily dose: 300 mg. Intravenous: 5-20 mg IV bolus, may repeat every 20-30 minutes as needed, or continuous IV infusion 0.5-10 mg/hour.
Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing.
The terminal elimination half-life of hydralazine is approximately 2–4 hours in patients with normal renal function, but it is prolonged in renal impairment (up to 7–16 hours). The antihypertensive effect often lasts longer than the half-life due to persistent binding to arteriolar receptors.
Primarily metabolized by glucuronidation via UGT1A1 and UGT1A3 enzymes; minor metabolites include minoxidil sulfate, which is active.
Extensively metabolized in the liver via N-acetylation (N-acetyltransferase 2, NAT2) and subsequent conjugation; also metabolized by cytochrome P450 (CYP) enzymes.
Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%).
Hydralazine is primarily metabolized in the liver via N-acetylation (polymorphic) and hydroxylation. Less than 10% of the dose is excreted unchanged in urine. The major metabolites are hydralazine pyruvic acid hydrazone and other conjugates, which are excreted renally. Fecal elimination is negligible.
About 20% bound to plasma proteins (primarily albumin).
Approximately 85–90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 3-4 L/kg, indicating extensive distribution into tissues.
1.5–1.8 L/kg. This large Vd indicates extensive distribution into tissues, including arteriolar smooth muscle.
Oral: Approximately 90% absorbed, but bioavailability is around 50% due to first-pass metabolism. Topical: Systemic absorption is minimal (approximately 1.4-5% of applied dose).
Oral bioavailability is about 26–50% due to significant first-pass metabolism. Bioavailability is higher in slow acetylators compared to rapid acetylators.
No dose adjustment required for topical minoxidil. For oral minoxidil (off-label for hypertension): GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 75%.
Cr Cl 10-50 m L/min: Administer every 8 hours. Cr Cl <10 m L/min: Administer every 8-16 hours. Dose reduction may be necessary to avoid accumulation.
No specific guidelines for topical minoxidil. For oral minoxidil: Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Child-Pugh Class A and B: No specific recommendations; use with caution. Child-Pugh Class C: Contraindicated due to risk of hepatotoxicity and reduced drug clearance.
Not recommended for use in children under 18 years for androgenetic alopecia. Safety and efficacy not established.
Oral: 0.75-1 mg/kg/day divided every 6-12 hours, maximum 5 mg/kg/day. Intravenous: 0.1-0.2 mg/kg/dose IV every 4-6 hours as needed, maximum 0.5 mg/kg/dose (20 mg).
No specific dose adjustment required for topical use. Monitor for orthostatic hypotension or fluid retention with oral use. Start at lower end of dosing range if using oral minoxidil.
Initiate at lower doses (e.g., 10 mg 2-3 times daily) and titrate slowly due to increased risk of hypotension and drug accumulation; monitor renal function closely.
None
May cause a syndrome resembling systemic lupus erythematosus (SLE), especially with prolonged use or high doses.
Cardiovascular effects: tachycardia, fluid retention, pericardial effusion (rarely) – risk increases with systemic absorption; avoid use in patients with pheochromocytoma or hypertensive crisis,Hypotension: can occur if applied to broken skin or excessive application,Dermatologic: contact dermatitis, scalp irritation, unwanted facial hair growth (hypertrichosis),Cardiac: avoid in patients with known coronary artery disease or arrhythmias
May cause drug-induced lupus, peripheral neuritis (pyridoxine deficiency), myocardial infarction (precipitate angina), hypotension, tachycardia, and blood dyscrasias. Use with caution in patients with coronary artery disease, cerebrovascular disease, or renal impairment.
Hypersensitivity to minoxidil or any component of the formulation,Concurrent use with other topical hair growth products
Hypersensitivity to hydralazine, mitral valvular rheumatic heart disease, coronary artery disease, and idiopathic systemic lupus erythematosus.
No significant food interactions. Avoid excessive alcohol intake as it may worsen orthostatic hypotension if systemic absorption occurs.
Hydralazine absorption is significantly increased when taken with food; it is recommended to take with meals for consistent effect. Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) if combined with MAOIs, though hydralazine itself is not an MAOI. No specific dietary restrictions otherwise.
Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimester: Possible fetal hypotension, hypertrichosis, and perinatal complications. Avoid use in pregnant women unless benefit outweighs risk.
First trimester: Limited human data; animal studies show no teratogenicity. Second/third trimester: Associated with maternal hypotension and potential fetal distress; no known structural anomalies.
Minoxidil is excreted in human milk. M/P ratio not reported. Potential for adverse effects in nursing infant (e.g., hypotension, fluid retention). Use caution; decide based on importance of drug to mother.
Hydralazine is excreted into breast milk in small amounts (M/P ratio ~0.8). Considered compatible with breastfeeding by AAP; monitor infant for hypotension or drowsiness.
No specific dose adjustment guidelines. Due to increased plasma volume and renal clearance during pregnancy, effectiveness may be reduced; monitor response and adjust dose as needed, but avoid excessive hypotension. Use lowest effective dose.
Increased clearance in pregnancy may require higher doses to achieve same antihypertensive effect; start low and titrate based on blood pressure response.
Minoxidil extra strength (5%) is a topical vasodilator used for androgenetic alopecia. Onset of hair regrowth typically requires 4-6 months of twice-daily application. Initial shedding of telogen hairs may occur in the first 2-6 weeks due to synchronization of hair cycle. Use in patients with cardiovascular disease or those on antihypertensives may theoretically cause systemic effects but is rare at topical doses. Avoid concomitant use with other topical agents that may irritate scalp. Discontinue if no response after 12 months.
Hydralazine is a direct-acting arterial vasodilator; its antihypertensive effect is limited by reflex tachycardia and fluid retention, so it is typically used in combination with a beta-blocker and a diuretic. Slow acetylators are at increased risk of drug-induced lupus, especially with doses >200 mg/day. Administer with food to enhance bioavailability; onset of action occurs within 20-30 minutes IV. For hypertensive urgency, IV hydralazine 5-20 mg every 20-30 min is used, but avoid in suspected myocardial ischemia due to reflex tachycardia.
Apply 1 m L to dry scalp twice daily, spreading evenly over affected areas.,Wash hands thoroughly after application to avoid unwanted hair growth.,Initial hair shedding is normal and indicates drug is working; do not stop.,Visible results may take 4-6 months; treatment is lifelong to maintain benefits.,Avoid contact with eyes, mouth, and broken skin; if contact occurs, rinse with water.,Do not use more than directed; systemic side effects are rare but include dizziness and rapid heartbeat.
Take exactly as prescribed, with food or milk to increase absorption.,Do not stop abruptly; sudden cessation can cause severe rebound hypertension.,Report symptoms like chest pain, rapid heartbeat, joint pain, rash, or fever to your doctor.,Avoid alcohol and other antihypertensives unless approved by your doctor.,Inform your doctor if you become pregnant or plan to become pregnant.,May cause dizziness; rise slowly from sitting or lying down.
"Isocarboxazid, a monoamine oxidase inhibitor (MAOI), increases the risk of severe hypotension when combined with minoxidil, a direct-acting vasodilator used for hypertension. The MAOI potentiates the hypotensive effects of minoxidil by inhibiting the metabolism of norepinephrine and other vasoactive amines, leading to exaggerated vasodilation and blood pressure reduction. Clinically, this can result in symptomatic hypotension, dizziness, syncope, and potentially cardiovascular collapse."
"Morphine and minoxidil coadministration can lead to additive hypotensive effects, increasing the risk of severe orthostatic hypotension and syncope. Morphine's vasodilatory properties via histamine release and opioid-induced reduction in sympathetic tone synergize with minoxidil's direct arterial vasodilation, potentially causing a precipitous drop in blood pressure. This interaction is particularly concerning in patients with compromised cardiovascular function or volume depletion, and may necessitate dose adjustments or avoidance."
"Minoxidil, a potent arterial vasodilator used in hypertension and alopecia, can enhance the hypotensive effects of epoprostenol, a prostacyclin analog that directly dilates pulmonary and systemic arteries. The combined vasodilatory action may lead to additive reductions in systemic blood pressure, potentially causing hypotension, dizziness, or syncope, especially during intravenous epoprostenol infusion for pulmonary arterial hypertension. Clinical outcomes may include orthostatic hypotension, reflex tachycardia, and compromised organ perfusion if doses are not adjusted."
"Oxaprozin, a nonsteroidal anti-inflammatory drug (NSAID), can reduce the antihypertensive efficacy of hydralazine, a direct-acting vasodilator. NSAIDs inhibit prostaglandin synthesis, which can lead to sodium and fluid retention and increased vascular resistance, thereby counteracting the vasodilatory effects of hydralazine. This interaction may result in diminished blood pressure control and require dosage adjustments or alternative therapies."
"Hydralazine, a direct-acting vasodilator, may reduce the antihypertensive efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) like sulindac. NSAIDs inhibit cyclooxygenase-mediated prostaglandin synthesis, leading to sodium retention and increased vascular tone, which can antagonize the vasodilatory effects of hydralazine. This interaction may result in elevated blood pressure and diminished control of hypertension in patients receiving both agents."
"Hydralazine, a direct-acting vasodilator, may reduce the antihypertensive efficacy of Tolfenamic acid, a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase (COX) enzymes. The interaction arises because Tolfenamic acid's inhibition of COX-2 reduces synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the vascular endothelium, which counteracts the vasodilation induced by Hydralazine. Clinically, this can lead to blunted blood pressure reduction, potentially requiring dose adjustments or alternative therapies to maintain adequate hypertension control."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINOXIDIL EXTRA STRENGTH (FOR MEN) vs HYDRALAZINE HYDROCHLORIDE, answered by our medical review team.
MINOXIDIL EXTRA STRENGTH (FOR MEN) is a Vasodilator / Hair Growth Stimulant that works by Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.. HYDRALAZINE HYDROCHLORIDE is a Vasodilator that works by Vasodilation of arterioles by direct relaxation of vascular smooth muscle, likely involving interference with calcium movement.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINOXIDIL EXTRA STRENGTH (FOR MEN) and HYDRALAZINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINOXIDIL EXTRA STRENGTH (FOR MEN) is: Topical: 1 m L of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 m L (100 mg).. The standard adult dose of HYDRALAZINE HYDROCHLORIDE is: Oral: Initiate with 10 mg 4 times daily for 2-4 days, then increase to 25 mg 4 times daily for the remainder of the week, then titrate to 50 mg 4 times daily. Maximum daily dose: 300 mg. Intravenous: 5-20 mg IV bolus, may repeat every 20-30 minutes as needed, or continuous IV infusion 0.5-10 mg/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINOXIDIL EXTRA STRENGTH (FOR MEN) and HYDRALAZINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINOXIDIL EXTRA STRENGTH (FOR MEN) is classified as Category A/B. Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimes. HYDRALAZINE HYDROCHLORIDE is classified as Category A/B. First trimester: Limited human data; animal studies show no teratogenicity. Second/third trimester: Associated with maternal hypotension and potential fetal distress; no known stru. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.